Conference Coverage

T1D neuropathy declines as glycemic control improves


 

REPORTING FROM ADA 2018

“We have the ability to prevent neuropathy, and we should do that to our advantage, targeting glycemic control as best as possible without increasing the risk of hypoglycemia,” Dr. Mizokami-Stout said. Targeting nonglycemic factors is also crucial, she said.

The study was funded by the Helmsley Charitable Trust. Dr. Mizokami-Stout and Dr. Pop-Busui report no relevant disclosures. Some of the other authors report various disclosures.

SOURCE: Mizokami-Stout K, et al. ADA 2018, Abstract 62-OR.

Pages

Recommended Reading

The case for bariatric surgery to manage CV risk in diabetes
MDedge Internal Medicine
Thyroid markers linked to risk of gestational diabetes
MDedge Internal Medicine
Type 2 diabetes may promote Parkinson development
MDedge Internal Medicine
NIH cans study that relied on millions in funding from alcohol companies
MDedge Internal Medicine
In T2DM, healthy lifestyle lowers CVD risk, mortality
MDedge Internal Medicine
Diabetic foot ulcer healing is predictable by WIfI stage scores
MDedge Internal Medicine
Ethical violations scuttle NIH’s big alcohol study
MDedge Internal Medicine
FDA okays fully implantable continuous glucose monitor/mobile app combo for diabetes
MDedge Internal Medicine
Patients going without as insulin prices skyrocket
MDedge Internal Medicine
Average glucose, A1c discordance is common, highlights ADAG equation concerns
MDedge Internal Medicine